Company Summary
Search
Home Page
 
Acasti Pharma Inc. 
Listed Company 
Current   Past  
Fiscal Year EndCompany StatusExempt Flag
February 29TradingN
Board of Directors
NamePosition
Adrian Montgomery  Director of the Board
Andre Godin  Interim
Harlan Waksal  Director of the Board
Jerald J. Wenker  Director of the Board
Pierre Fitzgibbon  Director of the Board
Reed V. Tuckson  Director of the Board
Ronald Denis  Chairperson of the Board
  Director of the Board
Valier Boivin  Director of the Board
Incorporation Locations
Inc. DateExpiry DateCountryRegionDescription
1/Feb/2002  Canada Quebec  
Exchange Filing Office
Location
Montreal Regional Service Office
Business Type(s)
Primary/SecondaryBusiness TypeDetails
Primary  Research and Development in the Physical, Engineering and Life Sciences  From News Release May 23, 2014 - Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and PUFAs, mainly eicosapentaenoic acid ("EPA") and docosahexaenoic acid ("DHA"), which are two types of omega-3 fatty acids well known to be beneficial for human health. CaPre(R), currently Acasti's only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. 
Securities
SymbolSecurity NameMarketStatus
APOAcasti Pharma Inc.TSX VentureTRADING
Name HistoryFromTo
Acasti Pharma Inc.1/Feb/2002Present
Company Facts Reconciliation
SubjectDate Returned
Fall 2014 CFRNot Received
Associations
Auditing Firm:  KPMG LLP
Transfer Agent:  Computershare Investor Services Inc.
Latest Information
TypeDateTitle
News Releases  11/Nov/2014  NEWS RELEASE - RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM B[MARKET NEWS]
    NEWS RELEASE - POSITIVE TOP LINE PHARMACOKINETIC RESULTS[MARKET NEWS]
    NEWS RELEASE - ORAL PRESENTATION ON COLT STUDY RESULTS AT 19TH[MARKET NEWS]
Bulletins  21/Feb/2014  PP-N-B
Meetings and Public Filings  Information on financial statements, public filings and corporate meetings for all Canadian public companies can be found at www.sedar.com
Property Locations
(not available)

* Historical Data